Thrombocytosis and hematocrit as prognostic factors in renal carcinoma.
暂无分享,去创建一个
Carlos Javier Ortega Seda | Alberto San Juan Salas | Cristina García Sánchez | José María Lozano Blasco | Ignacio Osman García | José Manuel Conde Sánchez | Carmen Belén Congregado Ruíz | Salvador Mármol Navarro | Rafael Antonio Medina López | R. A. López | S. Navarro | C. B. C. Ruíz | I. García | J. M. C. Sánchez | A. Salas | C. Seda | C. G. Sanchez | J. M. L. Blasco
[1] W. Dik,et al. Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour. , 2009, The Netherlands journal of medicine.
[2] J. Patard,et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. , 2007, European urology.
[3] R. Figlin,et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] F. Guillé,et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. , 2004, The Journal of urology.
[5] F. Erdemir,et al. Clinical Significance of Platelet Count in Patients with Renal Cell Carcinoma , 2007, Urologia Internationalis.
[6] J L Warren,et al. Rising incidence of renal cell cancer in the United States. , 1999, JAMA.
[7] H. Joensuu,et al. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] A. Belldegrun,et al. The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.
[9] S. Campbell,et al. Prognostic factors in renal cell carcinoma. , 2003, The Urologic clinics of North America.
[10] H. Verheul,et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. , 2000, Blood.
[11] M. Kattan,et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.
[12] S. J. Kim,et al. Prognostic Significance of Preoperative C-Reactive Protein Elevation and Thrombocytosis in Patients with Non-Metastatic Renal Cell Carcinoma , 2011, Korean journal of urology.
[13] I. Cho,et al. A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma , 2008, Yonsei medical journal.
[14] D. McMillan,et al. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse‐free and cancer‐specific survival in patients undergoing potentially curative resection for renal cancer , 2008, BJU international.
[15] K. Bensalah,et al. Prognostic value of thrombocytosis in renal cell carcinoma. , 2006, The Journal of urology.
[16] P. Lindblad. Epidemiology of Renal Cell Carcinoma , 2004, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
[17] S. Fuhrman,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.
[18] G. Nabi,et al. Correlation of percentage changes in platelet counts with recurrence rate following radical nephrectomy , 2010, Indian journal of urology : IJU : journal of the Urological Society of India.
[19] M. Brunelli,et al. Risk stratification and prognostication of renal cell carcinoma , 2008, World Journal of Urology.
[20] T. H. Klotz,et al. Impact of clinical variables on predicting disease‐free survival of patients with surgically resected renal cell carcinoma , 2009, BJU international.
[21] T. Mekhail,et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Ogan,et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. , 2010, The Journal of urology.
[23] P. Karakiewicz,et al. Predicting cancer-control outcomes in patients with renal cell carcinoma , 2007, Current opinion in urology.
[24] K. Ito,et al. Impact of thrombocytosis and C‐reactive protein elevation on the prognosis for patients with renal cell carcinoma , 2006, International journal of urology : official journal of the Japanese Urological Association.
[25] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] N. Rioux-Leclercq,et al. Prognostic significance of the mode of detection in renal tumours , 2002, BJU international.
[27] Xin Lu,et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis , 2011, Journal of Cancer Research and Clinical Oncology.
[28] Z. Kırkalı,et al. Renal cell carcinoma: new prognostic factors? , 2003, Current opinion in urology.
[29] F. Marshall,et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. , 2002, The Journal of urology.